Four-Year Follow-Up Confirms Lenvatinib/Pembrolizumab Safety in RCC

Commentary
Video

Common adverse effects following treatment with lenvatinib plus pembrolizumab in the phase 3 CLEAR study include diarrhea, hypertension, and fatigue, according to Thomas E. Hutson, DO, PharmD, FACP.

In an interview with CancerNetwork®, Thomas E. Hutson, DO, PharmD, FACP, spoke about how the safety profile of pembrolizumab (Keytruda) plus lenvatinib (Lenvima) in patients with advanced clear cell renal cell carcinoma (RCC) was maintained after 4 years of follow-up in the phase 3 CLEAR study (NCT0281186).1

Hutson, director of the Urologic Oncology Program and co-chair of the Urologic Cancer Research and Treatment Center at Baylor University Medical Center in Dallas, as well as a professor of Medicine at Texas A&M College of Medicine, said that any adverse effects (AEs) in the trial were manageable with dose interruptions, reductions, or modifications in combination with best supportive care. Additionally, the 4-year follow-up safety data were consistent with reports from the initial preliminary analysis of the CLEAR study that led to the regimen’s regulatory approval.

The FDA approved lenvatinib plus pembrolizumab for this patient population in August 2021.2

According to data presented at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting, the most common any-grade treatment-related AEs in the lenvatinib plus pembrolizumab and sunitinib (Sutent) arms, respectively, included diarrhea (56.0% vs 46.3%), hypertension (54.3% vs 40.3%), hypothyroidism (44.9% vs 24.1%), and decreased appetite (35.5% vs 26.3%).

Transcript:

The safety—as reported in the initial preliminary analysis of the data that resulted in [lenvatinib plus pembrolizumab's] regulatory approval—is maintained, confirming that there are no new additional safety signals with longer follow-up. The diarrhea, hypertension, and fatigue, which are the most commonly reported [adverse] effects, are there throughout the therapy with no additional worsening in the way that the [adverse] effects are managed, as is indicated in the product labeling, through dose interruption, dose reduction, and then best supportive care.

This continues to be the strategy we want to employ in managing the [adverse] effects and keeping the dose intensity where it needs to be so that patients get this long-term benefit from therapy.

References

  1. Motzer RJ, Porta C, Eto M, et al. Final prespecified overall survival (OS) analysis of CLEAR: 4-year follow-up of lenvatinib plus pembrolizumab (L+P) vs sunitinib (S) in patients (pts) with advanced renal cell carcinoma (aRCC). J Clin Oncol. 2023;41(suppl 16):4502. doi:10.1200/JCO.2023.41.16_suppl.4502
  2. FDA approves Keytruda (pembrolizumab) plus Lenvima (lenvatinib) combination for first-line treatment of adult patients with advanced renal cell carcinoma (RCC). News release. Merck. August 11, 2021. Accessed July 19, 2023. https://bwnews.pr/3m0p3Vh

Newsletter

Stay up to date on recent advances in the multidisciplinary approach to cancer.

Recent Videos
Extravasation with beta emitters may elicit more drastic adverse effects due to their higher radiation dose.
Increasing the use of patient-reported outcomes may ensure that practitioners can fully ascertain the impact of treatment for rare lymphomas.
Photographic and written documentation can help providers recognize inflammatory breast cancer symptoms across diverse populations.
The use of guideline-concordant care in breast cancer appears to be more common in White populations than Black populations.
Retrospective and real-world registry studies may be necessary to guide clinical decision-making for rarer lymphomas with insufficient prospective data.
Extravasation results in exposing healthy tissue to radiation, which can be highly dosed depending on the isotope used for treatment.
Ongoing studies seek to evaluate immunotherapy in earlier lines of therapy for patients with early-stage Hodgkin lymphoma.
Strict inclusion criteria may disproportionately exclude racial minority populations from participating in breast cancer trials.
Related Content